THE AMERICAN SOCIETY OF GENE & CELL THERAPY
Income Statement
Fiscal Year Start:
Jan 1
Revenues in 2024
$16,914,337
Program Services
92%
Investments
6%
Contributions
1%
Other
<1%
Government Grants
0%
Fundraising Events
0%
Membership Dues
0%
Expenses in 2024
$14,579,126
Other
36%
Salaries & Benefits
36%
Offices, Occupancy & IT
10%
Grants
9%
Fees to Service Providers
6%
Advertising & Promotion
3%
Depreciation
<1%
Benefits to Members
0%
Interest
0%
Revenues
2023
2024
Change
Contributions
$1,051,877
$229,856
-78%
Government Grants
$0
$0
-
Fundraising Events
$0
$0
-
Program Services
$14,604,317
$15,624,301
+7%
Membership Dues
$0
$0
-
Investments
$643,264
$1,024,374
+59%
Other
$71,250
$35,806
-50%
Total Revenues
$16,370,708
$16,914,337
+3%
Expenses
2023
2024
Change
Grants
$1,853,948
$1,266,770
-32%
Benefits to Members
$0
$0
-
Salaries & Benefits
$4,400,143
$5,250,736
+19%
Fees to Service Providers
$891,684
$824,060
-8%
Advertising & Promotion
$488,870
$484,976
-1%
Offices, Occupancy & IT
$1,212,519
$1,416,386
+17%
Interest
$0
$0
-
Depreciation
$55,236
$55,094
0%
Other
$4,852,227
$5,281,104
+9%
Total Expenses
$13,754,627
$14,579,126
+6%
Net income
2023
2024
Change
Net income
+$2,616,081
+$2,335,211
-11%
Functional Expenses
Summary
2023
2024
Change
Program
$11,240,882
$11,680,451
+4%
Admin
$1,818,472
$2,075,815
+14%
Fundraising
$695,273
$822,860
+18%
Total Expenses
$13,754,627
$14,579,126
+6%
Copyright 2026. All rights reserved to Chario Inc. (d.b.a. Impala)